Thera-SAbDab

SECUKINUMAB

>   Structural Summary
TherapeuticSecukinumab
TargetIL17A
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK
100% seqID Fv Structure6wio [Fvs: AB], 6wir [Fvs: AB]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyAbgenix XenoMouse
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedBeth Israel Deaconess Medical Center, GWT-TUD GmbH, Icahn School of Medicine at Mount Sinai, Novartis, Alcon
Conditions ApprovedAnkylosing spondylitis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis
Conditions ActiveHidradenitis suppurativa, Juvenile rheumatoid arthritis, Non-radiographic axial spondyloarthritis, Rheumatoid arthritis, Alopecia areata, Atopic dermatitis, Giant cell arteritis, Necrobiosis lipoidica, Tendon injuries
Conditions DiscontinuedAsthma, Crohn's disease, Dry eyes, Multiple sclerosis, Polymyalgia rheumatica, Type 1 diabetes mellitus, Uveitis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]